BioMed Realty Trust Beats Up on Analysts Yet Again

Before you go, we thought you'd like these...
Before you go close icon

BioMed Realty Trust (NYS: BMR) reported earnings on Feb. 9. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended Dec. 31 (Q4), BioMed Realty Trust met expectations on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue increased and GAAP earnings per share improved significantly.

Margins grew across the board.

Revenue details
BioMed Realty Trust recorded revenue of $112.4 million. The nine analysts polled by S&P Capital IQ predicted a top line of $111.4 million on the same basis. GAAP reported sales were 18% higher than the prior-year quarter's $101.8 million.

anImage

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at $0.09. The six earnings estimates compiled by S&P Capital IQ anticipated $0.05 per share. GAAP EPS of $0.09 for Q4 were 50% higher than the prior-year quarter's $0.06 per share.

anImage

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 73.9%, 470 basis points better than the prior-year quarter. Operating margin was 35.1%, 380 basis points better than the prior-year quarter. Net margin was 13.1%, 60 basis points better than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $115.9 million. On the bottom line, the average EPS estimate is $0.07.

Next year's average estimate for revenue is $478.2 million. The average EPS estimate is $0.27.

Investor sentiment
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 71 members out of 88 rating the stock outperform, and 17 members rating it underperform. Among 34 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 31 give BioMed Realty Trust a green thumbs-up, and three give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on BioMed Realty Trust is hold, with an average price target of $20.33.

Can your portfolio provide you with enough income to last through retirement? You'll need more than BioMed Realty Trust. Learn how to maximize your investment income and "Secure Your Future With 11 Rock-Solid Dividend Stocks." Click here for instant access to this free report.

At the time this article was published Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners